CD274 and neoplasm: The therapeutic flow of stage IVC cases shared this solution with stage IVB cases when carrying BRAFV600E mutation, and immunotherapy targeting PD-1/PD-L1 was recommended under the high PD-L1 expression or tumor mutational burden higher than ten mutations.